Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
21,062
Total Claims
$5.3M
Drug Cost
1,390
Beneficiaries
$3,807
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+58%
Opioid rate vs peers
3.5% vs 2.2% avg
+170%
Cost per patient vs peers
$3,807 vs $1,411 avg
+24%
Brand preference vs peers
13.2% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
3.5%
Opioid Rate
746
Opioid Claims
$21K
Opioid Cost
5.0%
Long-Acting Rate
Brand vs Generic
Brand: 2,759 claims · $4.6M
Generic: 18,187 claims · $637K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Bictegrav/Emtricit/Tenofov Ala | 182 | $833K |
| Emtricitab/Rilpiviri/Tenof Ala | 119 | $483K |
| Cabotegravir/Rilpivirine | 38 | $247K |
| Emtricitabine/Tenofov Alafenam | 78 | $211K |
| Abacavir/Dolutegravir/Lamivudi | 51 | $204K |
| Dolutegravir/Rilpivirine | 51 | $198K |
| Dulaglutide | 130 | $192K |
| Apixaban | 126 | $163K |
| Empagliflozin | 120 | $161K |
| Semaglutide | 104 | $138K |
| Darunavir/Cobicistat | 51 | $126K |
| Elviteg/Cob/Emtri/Tenof Alafen | 22 | $88K |
| Dolutegravir Sodium/Lamivudine | 26 | $81K |
| Rivaroxaban | 66 | $72K |
| Dapagliflozin Propanediol | 60 | $70K |
Prescribing Profile
Patient Profile
76
Avg Age
33%
Female
2.06
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data